Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
Medicine Medical Specialties Infectious Diseases Cancers Prostate Cancer Coronavirus Influenza Leukemia Vaccination Vaccines Virus Influenza Vaccine Malaria Virology Seasonal/Pandemic Influenza Universal Flu Vaccine